Abstract: Aspects of the disclosure relate to cash handling devices that provide intelligent monitoring and management of cash cycles. A cash handling device having at least one processor, a communication interface, and memory may receive, from a mobile device, a request to process a pre-staged transaction. Subsequently, the cash handling device may generate and present a graphical identifier based on the mobile device requesting access to the cash handling device. Next, the cash handling device may verify that the mobile device is authorized to perform the pre-staged transaction based on the graphical identifier being scanned by the mobile device and cause a connection to be established between the cash handling device and the mobile device. Thereafter, the cash handling device may identify and process the pre-staged transaction associated with the mobile device. Then, the cash handling device may generate a notification indicating completed processing of the identified pre-staged transaction.

Abstract: A device includes a power antenna and a data antenna, along with a switch operable to selectively connect the data antenna to data circuitry under various conditions. For example, the switch may be opened to decouple the data antenna when charging circuitry is receiving power through the power antenna, or under other conditions indicating that charging may be available or desired, thereby allowing for relatively unimpeded and efficient wireless charging of a device. The switch may be closed to enable use of the data antenna by data circuitry when wireless charging activity is not present, or when other conditions indicate that wireless data is available for the device.

Abstract: The present is directed to compositions comprising regulatory T cell epitopes, wherein said epitopes comprises a polypeptide comprising at least a portion of SEQ NOS: 1-124 (and/or fragments and variants thereof), and optionally 1 to 12 additional amino acids distributed in any ratio on the N-terminus and/or C-terminus of the polypeptide of SEQ ID NOS: 1-124, as well as methods of producing and using the same.

Abstract: The present disclosure provides methods and computer-implemented systems for producing, procuring, or identifying a non-human animal or offspring thereof having one or more predetermined traits. Also disclosed herein are a computer implemented graphical user interface and database system containing information associated with one or more predetermined traits for use in generating a probability matrix containing an array of probability values pertaining to the likelihood of producing a non-human animal having one or more predetermined traits.

Abstract: A physically stable skin care composition with a continuous phase and a dispersed phase and a method for making the same. The continuous phase can include from about 0.5% to about 1.5% sodium hyaluronate with a weight average molecular weight from about 500,000 to about 1,000,000 Da according to the European Pharmacopoeia Method. The continuous phase can also include at least two thickening agents that can includes polyacrylamide polymers and copolymers and a carboxylic acid polymer. The dispersed phase can include silicone. The composition can have an average viscosity greater than 25,000 cP and the sodium hyaluronate can be fully hydrated.

Abstract: Provided herein are pharmaceutical compositions comprising a Fe2+-exchanged fluorinated synthetic smectite and a synthetic semiconducting metal sulfide. The compositions can be used to treat topical conditions and gastrointestinal ailments, and can be incorporated into wound dressings, hydrogels, personal protective equipment, and 3D printed articles. Also provided are methods of synthesizing the Fe2+-exchanged fluorinated synthetic smectite and methods of making the synthetic semiconducting metal sulfide.

Abstract: A method for structuring a surface of an implant (100) made from a plastic material by means of a counter-body (200) comprises the following steps: providing (S110) of a counter-body (200) including a surface (210); forming (S120) of a first surface structure (212) on the surface (210) of the counter-body, wherein a first surface structure (212) comprises a non-regular, randomly distributed pattern; and forming (S130) of a second surface structure (112) on the implant (100) by using the counter-body (200), wherein the second surface structure and the first surface structure (212) are complementary to each other.

Abstract: The invention concerns a monoclonal antibody directed against mammalian aurora-A kinase, the method for obtaining same, as we ll as its uses in cancer diagnosis and prognosis, and in pharmaceutical compositions for cancer treatment.

Abstract: The present invention provides compositions and methods for cytoprotection. In particular, it provides zinc chelate compositions comprising at least one zinc ion and at least one aminothiol ligand.

Abstract: The invention concerns a monoclonal antibody directed against mammalian aurora-A kinase, the method for obtaining same, as well as its uses in cancer diagnosis and prognosis, and in pharmaceutical compositions for cancer treatment.

Abstract: This invention is related to a novel sample preparation, probes, couple primer sets for one step real time reverse transcriptase polymerise chain reaction (RT-PCR), methods and kits for the universal detection of alive bacteria and/or fungus-yeast in pharmaceutical, cosmetic and non clinical samples.

Abstract: Compounds having the formula (I): ##STR1## and stereoisomers thereof, wherein A is hydrogen, halo, hydroxy, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, C.sub.1-4 haloalkyl, C.sub.1-4 haloalkoxy, C.sub.1-4 alkylcarbonyl, C.sub.1-4 alkoxycarbonyl, phenoxy, nitro or cyano; R.sup.1 and R.sup.2, which may be the same or different, are hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclylalkyl, optionally substituted cycloalkylalkyl, optionally substituted aralkyl, optionally substituted heteroarylalkyl, optionally substituted aryloxyalkyl, optionally substituted heteroaryloxyalkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryloxy, optionally substituted heteroaryloxy, nitro, halo, cyano, --NR.sup.3 R.sup.4, --Co.sub.2 R.sup.3, --CONR.sup.3 R.sup.4, --COR.sup.3, --S(O).sub.n R.sup.3 wherein n is 0, 1 or 2, (CH.sub.2).sub.m PO(OR.

Abstract: Compounds having the formula (I): ##STR1## and stereoisomers thereof, wherein A is hydrogen, halo, hydroxy, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, C.sub.1-4 haloalkyl, C.sub.1-4 haloalkoxy, C.sub.1-4 alkylcarbonyl, C.sub.1-4 alkoxycarbonyl, phenoxy, nitro or cyano; R.sup.1 and R.sup.2, which may be the same or different, are hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclylalkyl, optionally substituted cycloalkylalkyl, optionally substituted aralkyl, optionally substituted heteroarylalkyl, optionally substituted aryloxyalkyl, optionally substituted heteroaryloxyalkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryloxy, optionally substituted heteroaryloxy, nitro, halo, cyano, --NR.sup.3 R.sup.4, --CO.sub.2 R.sup.3, --CONR.sup.3 R.sup.4, --COR.sup.3, --S(O).sub.n R.sup.3 wherein n is 0, 1 or 2, (CH.sub.2).sub.m PO(OR.

Abstract: Compounds having the formula (I) : ##STR1## and stereoisomers thereof, wherein A is hydrogen, halo, hydroxy, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, C.sub.1-4 haloalkyl, C.sub.1-4 haloalkoxy, C.sub.1-4 alkylcarbonyl, C.sub.1-4 alkoxycarbonyl, phenoxy, nitro or cyano; R.sup.1 and R.sup.2, which may be the same or different, are hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclylalkyl, optionally substituted cycloalkylalkyl, optionally substituted aralkyl, optionally substituted heteroarylalkyl, optionally substituted aryloxyalkyl, optionally substituted heteroaryloxyalkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryloxy, optionally substituted heteroaryloxy, nitro, halo, cyano, --NR.sup.3 R.sup.4, --CO.sub.2 R.sup.3, --CONR.sup.3 R.sup.4, --COR.sup.3, --S(O).sub.n R.sup.3 wherein n is 0, 1 or 2, (CH.sub.2).sub.

Abstract: Compounds having the formula (I): ##STR1## and stereoisomers thereof, wherein A is hydrogen, halo, hydroxy, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, C.sub.1-4 haloalkyl, C.sub.1-4 haloalkoxy, C.sub.1-4 alkylcarbonyl, C.sub.1-4 alkoxycarbonyl, phenoxy, nitro or cyano; R.sup.1 and R.sup.2, which may be the same or different, are hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclylalkyl, optionally substituted cycloalkylalkyl, optionally substituted aralkyl, optionally substituted heteroarylalkyl, optionally substituted aryloxyalkyl, optionally substituted heteroaryloxyalkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryloxy, optionally substituted heteroaryloxy, nitro, halo, cyano, --NR.sup.3 R.sup.4, --CO.sub.2 R.sup.3, --CONR.sup.3 R.sup.4, --COR.sup.3, --S(O).sub.n R.sup.3 wherein n is 0, 1 or 2, (CH.sub.2).sub.m PO(OR.

Abstract: This invention relates to derivatives of propanoic acid of the formula ##STR1## Useful as fungicides, insecticides and miticides, to processes for preparing them, to compositions containing them, and to methods of using them to combat fungi, especially fungal infections of plants, and to kill or control insects and mites.